Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2016. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation and share allocations rather than corporate financial performance.
Material Changes
The primary material change reported is the allocation of notional Ordinary Shares and American Depositary Shares (ADSs) to Non-Executive Directors for the service period of January 1, 2016, to March 31, 2016. Additionally, Jesse Goodman was appointed to the Board effective January 1, 2016, with a specific arrangement to reinvest 25% of his fees into ADSs at a future date.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. It is a compliance disclosure regarding director interests.
Important Facts for Investors
- Allocation Date: Notional shares were allocated on March 31, 2016, with notification provided on April 1, 2016.
- Share Prices: Allocations were based on a price of £14.05 per Ordinary Share and $40.53 per ADS.
- Director Appointments: Jesse Goodman joined the Board on January 1, 2016, with deferred share reinvestment terms.
- Beneficiaries: Allocations were made to Sir Philip Hampton, Professor Sir Roy Anderson, Vindi Banga, Dr Stephanie Burns, Stacey Cartwright, Lynn Elsenhans, Judy Lewent, Sir Deryck Maughan, Dr Daniel Podolsky, Urs Rohner, and Hans Wijers.